SynthesisFrontiers in medicine2025
Impact of atropine on changes in choroidal thickness in children with myopia: a meta-analysis of randomized controlled trials.
Synthesis in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Effect of 0.01% Atropine on Choroidal Thickness and Ocular Growth in Pre-myopic Children.Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists) · 2026Trial
- Neuro-ophthalmic review on pediatric myopia: Advancing from refraction to a brain-centric model of axial growth.World journal of clinical pediatrics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Atropine is used to treat myopia, and choroidal thickness (ChT) has been suggested as a biomarker for treatment response. However, randomized controlled trials (RCTs) have reported inconsistent results regarding their efficacy. This study aimed to assess the effect of atropine on ChT in children with myopia. Methods: A systematic review and meta-analysis of RCTs was conducted using PubMed, Cochrane, Embase, and Web of Science databases, including trials registered online, from inception to March 2025. Eligible studies were those that involved patients aged <18 years with myopia treated using atropine sulfate eye drops and reported ChT outcomes. Meta-regression and the Cochrane Results: Overall, 11 RCTs involving 1,784 eyes of children with myopia were included. Four doses of atropine (0.01, 0.025, 0.05, and 0.1%) were administered. Subfoveal ChT (SFChT) significantly thickened in the atropine group compared with the control group (placebo or spectacles) during the trial periods [weighted mean difference (WMD): 11.83 μm, 95% confidence interval (CI): 0.88-22.79 μm, Conclusion: The results showed that atropine may increase ChT than control. Notably, 0.05% atropine may demonstrate the most favorable outcomes for ChT, spherical equivalent, and axial length. Systematic Review Registration: https://inplasy.com/?s=INPLASY202320027.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.